Literature DB >> 26405614

Relevance of low testosterone to non-alcoholic fatty liver disease.

Avni Mody1, Donna White2, Fasiha Kanwal3, Jose M Garcia4.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a condition where there is excess accumulation of triglycerides in the liver in the absence of excess alcohol consumption. It ranges from simple steatosis to non-alcoholic steatohepatitis (NASH), which can progress to fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). NAFLD, one of the most common causes of chronic liver disease in Western populations, is the hepatic component of the metabolic syndrome (MetS) and is associated with increased visceral adipose tissue (VAT), insulin resistance, and dyslipidemia. Studies have also shown that testosterone deficiency is associated with increased VAT and insulin resistance in males while hyperandrogenemia has been associated with increased risk of insulin resistance and VAT in females. Thus, the aims of this review are to discuss the available experimental and epidemiological data evaluating the association between testosterone and NAFLD, to discuss the potential clinical relevance of these data, and to identify gaps in the literature.

Entities:  

Keywords:  Liver diseases; endocrinology; hepatology; obesity; sex hormone-binding globulin

Year:  2015        PMID: 26405614      PMCID: PMC4577238          DOI: 10.1097/XCE.0000000000000057

Source DB:  PubMed          Journal:  Cardiovasc Endocrinol        ISSN: 2162-688X


  64 in total

Review 1.  Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?

Authors:  Mohamed Asrih; François R Jornayvaz
Journal:  Mol Cell Endocrinol       Date:  2015-02-24       Impact factor: 4.102

Review 2.  From the metabolic syndrome to NAFLD or vice versa?

Authors:  Ester Vanni; Elisabetta Bugianesi; Anna Kotronen; Samuele De Minicis; Hannele Yki-Järvinen; Gianluca Svegliati-Baroni
Journal:  Dig Liver Dis       Date:  2010-03-06       Impact factor: 4.088

Review 3.  Free testosterone: clinical utility and important analytical aspects of measurement.

Authors:  Jennifer L Shea; Pui-Yuen Wong; Yu Chen
Journal:  Adv Clin Chem       Date:  2014       Impact factor: 5.394

4.  Association Between Endogenous Sex Hormones and Liver Fat in a Multiethnic Study of Atherosclerosis.

Authors:  Mariana Lazo; Irfan Zeb; Khurram Nasir; Russell P Tracy; Matthew J Budoff; Pamela Ouyang; Dhananjay Vaidya
Journal:  Clin Gastroenterol Hepatol       Date:  2015-01-13       Impact factor: 11.382

5.  Activation of PKR/eIF2α signaling cascade is associated with dihydrotestosterone-induced cell cycle arrest and apoptosis in human liver cells.

Authors:  Rongyang Dai; Dongmei Yan; Juan Li; Shaokun Chen; Youping Liu; Run Chen; Chunyan Duan; Mei Wei; Hong Li; Tao He
Journal:  J Cell Biochem       Date:  2012-05       Impact factor: 4.429

6.  Testosterone replacement ameliorates nonalcoholic fatty liver disease in castrated male rats.

Authors:  L Nikolaenko; Y Jia; C Wang; M Diaz-Arjonilla; J K Yee; S W French; P Y Liu; S Laurel; C Chong; K Lee; Y Lue; W N P Lee; R S Swerdloff
Journal:  Endocrinology       Date:  2013-11-26       Impact factor: 4.736

Review 7.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

8.  Differential effects of estrogen/androgen on the prevention of nonalcoholic fatty liver disease in the male rat.

Authors:  Hua Zhang; Yuanwu Liu; Li Wang; Zhen Li; Hongwen Zhang; Jihua Wu; Nafis Rahman; Yangdong Guo; Defa Li; Ning Li; Ilpo Huhtaniemi; Suk Ying Tsang; George F Gao; Xiangdong Li
Journal:  J Lipid Res       Date:  2012-11-21       Impact factor: 5.922

9.  Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study).

Authors:  T Hugh Jones; Stefan Arver; Hermann M Behre; Jacques Buvat; Eric Meuleman; Ignacio Moncada; Antonio Martin Morales; Maurizio Volterrani; Ann Yellowlees; Julian D Howell; Kevin S Channer
Journal:  Diabetes Care       Date:  2011-03-08       Impact factor: 19.112

Review 10.  Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review.

Authors:  Farid Saad; Antonio Aversa; Andrea M Isidori; Louis J Gooren
Journal:  Curr Diabetes Rev       Date:  2012-03
View more
  11 in total

1.  Genetic Variation and Mendelian Randomization Approaches.

Authors:  Mojgan Yazdanpanah; Nahid Yazdanpanah; Despoina Manousaki
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

2.  Intrahepatic Fat Content and Markers of Hepatic Fibrosis in Obese Children.

Authors:  Wei Wu; Hongxi Zhang; Xiaoqin Xu; Ke Huang; Junfen Fu
Journal:  Int J Endocrinol       Date:  2016-02-04       Impact factor: 3.257

3.  Testosterone insulin-like effects: an in vitro study on the short-term metabolic effects of testosterone in human skeletal muscle cells.

Authors:  C Antinozzi; F Marampon; C Corinaldesi; E Vicini; P Sgrò; G B Vannelli; A Lenzi; C Crescioli; L Di Luigi
Journal:  J Endocrinol Invest       Date:  2017-05-15       Impact factor: 4.256

4.  Is nonalcoholic fatty liver disease associated with the development of prostate cancer? A nationwide study with 10,516,985 Korean men.

Authors:  Yoon Jin Choi; Dong Ho Lee; Kyung-Do Han; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim
Journal:  PLoS One       Date:  2018-09-19       Impact factor: 3.240

5.  Lipodystrophy-like features after total body irradiation among survivors of childhood acute leukemia.

Authors:  Sandrine Visentin; Gérard Michel; Claire Oudin; Béatrice Cousin; Bénédicte Gaborit; Inès Abdesselam; Marie Maraninchi; Marion Nowicki; René Valéro; Maxime Guye; Monique Bernard; Pascal Auquier; Hervé Chambost; Marie-Christine Alessi; Sophie Béliard
Journal:  Endocr Connect       Date:  2019-04       Impact factor: 3.335

6.  Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism.

Authors:  Hongmei Yan; Weiyun Wu; Xinxia Chang; Mingfeng Xia; Sicheng Ma; Liu Wang; Jian Gao
Journal:  Biol Sex Differ       Date:  2021-01-04       Impact factor: 5.027

7.  Protection against Osteoarthritis Symptoms by Aerobic Exercise with a High-Protein Diet by Reducing Inflammation in a Testosterone-Deficient Animal Model.

Authors:  Sunmin Park; Suna Kang; Da Sol Kim; Ting Zhang
Journal:  Life (Basel)       Date:  2022-01-26

8.  Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes.

Authors:  Kristin Alexandra Dayton; Fernando Bril; Diana Barb; Jinping Lai; Srilaxmi Kalavalapalli; Kenneth Cusi
Journal:  PLoS One       Date:  2021-06-02       Impact factor: 3.240

9.  AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease.

Authors:  Nikolaos Nikolaou; Laura L Gathercole; Lea Marchand; Sara Althari; Niall J Dempster; Charlotte J Green; Martijn van de Bunt; Catriona McNeil; Anastasia Arvaniti; Beverly A Hughes; Bruno Sgromo; Richard S Gillies; Hanns-Ulrich Marschall; Trevor M Penning; John Ryan; Wiebke Arlt; Leanne Hodson; Jeremy W Tomlinson
Journal:  Metabolism       Date:  2019-07-19       Impact factor: 8.694

10.  Testosterone treatment is associated with reduced adipose tissue dysfunction and nonalcoholic fatty liver disease in obese hypogonadal men.

Authors:  E Maseroli; P Comeglio; C Corno; I Cellai; S Filippi; T Mello; A Galli; E Rapizzi; L Presenti; M C Truglia; F Lotti; E Facchiano; B Beltrame; M Lucchese; F Saad; G Rastrelli; M Maggi; L Vignozzi
Journal:  J Endocrinol Invest       Date:  2020-08-08       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.